Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.

Fiche publication

Date publication

mai 2023

Journal

EBioMedicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François , Dr FUMET Jean-David , Pr BIBEAU Frédéric

Tous les auteurs :
Ghiringhelli F, Bibeau F, Greillier L, Fumet JD, Ilie A, Monville F, Laugé C, Catteau A, Boquet I, Majdi A, Morgand E, Oulkhouir Y, Brandone N, Adam J, Sbarrato T, Kassambara A, Fieschi J, Garcia S, Lepage AL, Tomasini P, Galon J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37244159

Résumé

Anti-PD-1 and PD-L1 antibodies (mAbs) are approved immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only a minority of patients responds to these treatments and biomarkers predicting response are currently lacking.